{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:47:23Z","timestamp":1791229643233,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Interstitial lung abnormalities (ILAs) are subtle or mild parenchymal abnormalities observed in more than 5% of the lungs on computed tomography (CT) scans in patients in whom interstitial lung disease was not previously clinically suspected and is considered. ILA is considered to be partly undeveloped stages of idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). This study aims to clarify the frequency of subsequent IPF or PPF diagnosis, the natural course from the preclinical status of the diseases, and the course after commencing treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is an ongoing, prospective, multicentre observational cohort study of patients with ILA referred from general health screening facilities with more than 70,000 annual attendances. Up to 500 participants will be enrolled annually over 3 years, with 5-year assessments every six months. Treatment intervention including anti-fibrotic agents will be introduced in disease progression cases. The primary outcome is the frequency of subsequent IPF or PPF diagnoses. Additionally, secondary and further endpoints are associated with the efficacy of early therapeutic interventions in cases involving disease progression, including quantitative assessment by artificial intelligence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This is the first prospective, multicentre, observational study to clarify (i) the aetiological data of patients with ILA from the largest general health check-up population, (ii) the natural course of IPF or PPF from the asymptomatic stage, and (iii) the effects and outcomes of early therapeutic intervention including anti-fibrotic agents for progressive cases of ILA. The results of this study could significantly impact the clinical practice and treatment strategy for progressive fibrosing interstitial lung diseases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration number<\/jats:title>\n                <jats:p>UMIN000045149.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-023-02455-y","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T14:02:41Z","timestamp":1686232961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["An observational cohort study of interstitial lung abnormalities (ILAs) in a large Japanese health screening population (Kumamoto ILA study in Japan: KILA-J)"],"prefix":"10.1186","volume":"23","author":[{"given":"Kazuya","family":"Ichikado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Ichiyasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Iyonaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kodai","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noritaka","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Johkoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiminori","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Morinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Mitsuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritaka","family":"Suga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Handa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyohiro","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Sakagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"2455_CR1","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S2213-2600(20)30168-5","volume":"8","author":"H Hatabu","year":"2020","unstructured":"Hatabu H, Hunninghake GM, Richeldi R, Brown KK, Wells AU, Remy-Jardin M, et al. Interstitial lung abnormalities detected incidentally on CT: a position paper from the Fleischner Society. Lancet Respir Med. 2020;8:726\u2013737.","journal-title":"Lancet Respir Med"},{"key":"2455_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1148\/radiol.2018181684","volume":"291","author":"H Hatabu","year":"2019","unstructured":"Hatabu H, Hunninghake GM, Lynch D. Interstitial lung abnormality: recognition and perspectives. Radiology. 2019;291:1\u20133.","journal-title":"Radiology"},{"key":"2455_CR3","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1056\/NEJMoa1007285","volume":"364","author":"G Washko","year":"2011","unstructured":"Washko G, Hunninghake GM, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med. 2011;364:897\u2013906.","journal-title":"N Engl J Med"},{"key":"2455_CR4","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1136\/thoraxjnl-2018-212446","volume":"74","author":"G Hunninghake","year":"2019","unstructured":"Hunninghake G. Interstitial lung abnormalities: erecting fences in the path towards advanced pulmonary fibrosis. Thorax. 2019;74:506\u2013511.","journal-title":"Thorax"},{"key":"2455_CR5","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S2213-2600(21)00017-5","volume":"9","author":"P Spagnolo","year":"2021","unstructured":"Spagnolo P, Ryerson CJ, Putman R, Oldham J, Salisbury M, Sverzellati N, et al. Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities. Lancet Respir Med. 2021:9:1065\u20131076.","journal-title":"Lancet Respir Med"},{"key":"2455_CR6","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1001\/jama.2016.0518","volume":"315","author":"RK Putman","year":"2016","unstructured":"Putman RK, Hatabu H, Araki T, Gudmundsson G, Gao W, Nishino M, et al. Association between interstitial lung abnormalities and all-cause mortality. JAMA. 2016;315:672\u2013681.","journal-title":"JAMA"},{"key":"2455_CR7","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi R, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice Guideline. Am J Respir Crit Care Med. 2022;205:e18\u2013e47.","journal-title":"Am J Respir Crit Care Med"},{"key":"2455_CR8","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.chest.2021.06.049","volume":"160","author":"T Petnak","year":"2021","unstructured":"Petnak T, Lertjitbanjong P, Thongprayoon, C, Moua R. Impact of antifibrotic therapy on mortality and acute exacerbation in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Chest. 2021;160:1751\u20131763.","journal-title":"Chest"},{"key":"2455_CR9","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1513\/AnnalsATS.202103-343OC","volume":"19","author":"M Ghazipura","year":"2022","unstructured":"Ghazipura M, Mammen MJ, Herman DD, Hon SM, Bissell BD, Macrea M, et al. Nintedanib in progressive pulmonary fibrosis: a systematic review and meta-analysis. Ann Am Thorac Soc. 2022;19:1040\u20131049.","journal-title":"Ann Am Thorac Soc"},{"key":"2455_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1164\/rccm.201809-1652OC","volume":"200","author":"RK Putman","year":"2019","unstructured":"Putman RK, Gudmundsson G, Axelsson GT, Hida T, Honda O, Araki T, et al. Imaging patterns are associated with interstitial lung abnormality progression and mortality. Am J Respir Crit Care Med. 2019;200:175\u2013183.","journal-title":"Am J Respir Crit Care Med"},{"key":"2455_CR11","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1164\/rccm.201512-2523OC","volume":"194","author":"T Araki","year":"2016","unstructured":"Araki T, Putman RK, Hatabu H, Gao W, Dupuis J, Latourelle JC, et al. Development and progression of interstitial lung abnormalities in the Framingham Heart Study. Am J Respir Crit Care Med. 2016;194:1514\u20131522.","journal-title":"Am J Respir Crit Care Med"},{"key":"2455_CR12","doi-asserted-by":"publisher","first-page":"e221172","DOI":"10.1148\/radiol.221172","volume":"306","author":"JE Lee","year":"2023","unstructured":"Lee JE, Chae KJ, Suh YJ, Jeong WG, Lee T, Kim Y-H, et al. Prevalence and long-term outcomes of CT interstitial lung abnormalities in a health screening cohort. Radiology. 2023;306:e221172.","journal-title":"Radiology"},{"key":"2455_CR13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1513\/AnnalsATS.202101-044OC","volume":"19","author":"T Handa","year":"2022","unstructured":"Handa T, Tanizawa K, Oguma T, Uozumi R, Watanabe K, Tanabe N, et al. Novel artificial intelligence-based technology for chest computed tomography analysis of idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2022;19:399\u2013406.","journal-title":"Ann Am Thorac Soc"},{"key":"2455_CR14","doi-asserted-by":"publisher","first-page":"2102269","DOI":"10.1183\/13993003.02269-2021","volume":"61","author":"H Nishikiori","year":"2023","unstructured":"Nishikiori H, Kuronuma K, Hirota K, Yama N, Suzuki T, Onodera M, et al. Deep learning algorithm to detect fibrosing interstitial lung disease on chest radiographs. Eur Respir J. 2023;61:2102269.","journal-title":"Eur Respir J"},{"key":"2455_CR15","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","volume":"8","author":"PM George","year":"2020","unstructured":"George PM, Spagnolo P, Kreuter M, Altinisik G, Bonifazi M, Martinez FJ, et al. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med. 2020;8:925\u2013934.","journal-title":"Lancet Respir Med"},{"key":"2455_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12931-023-02359-9","volume":"24","author":"AS Patel","year":"2023","unstructured":"Patel AS, Miller E, Regis SM, Hunninghake GM, Price LL, Gawlik M, et al. Interstitial lung abnormalities in a large clinical lung cancer screening cohort: association with mortality and ILD diagnosis. Respir Res. 2023;24:49.","journal-title":"Respir Res"},{"key":"2455_CR17","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1007\/s00330-021-08378-8","volume":"32","author":"KJ Chae","year":"2022","unstructured":"Chae KJ, Chung MJ, Jin GY, Song YJ, An AR, Choi H, et al. Radiologic-pathologic correlation of interstitial lung abnormalities and predictors for progression and survival. Eur Radiol. 2022;32:2713\u20132723.","journal-title":"Eur Radiol"},{"key":"2455_CR18","doi-asserted-by":"crossref","unstructured":"Hunninghake GM, Goldin JG, Kadoch MA, Kropski JA, Rosas IO, Wells AU, et al. Detection and early referral of patients with interstitial lung abnormalities: an expert survey initiative. Chest. 2022;161:470\u2013482.","DOI":"10.1016\/j.chest.2021.06.035"},{"key":"2455_CR19","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1164\/rccm.201109-1618OC","volume":"185","author":"T Doyle","year":"2012","unstructured":"Doyle T, Washko GR, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, et al. Interstitial lung abnormalities and reduced exercise capacity. Am J Crit Care Med. 2012;185:756\u2013762.","journal-title":"Am J Crit Care Med"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02455-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-023-02455-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02455-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T14:02:43Z","timestamp":1686232963000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-023-02455-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2455"],"URL":"https:\/\/doi.org\/10.1186\/s12890-023-02455-y","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]},"assertion":[{"value":"23 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KIchi, HI, TJ, and TS received lecture fees from Nippon Boehringer Ingelheim Co. Ltd. NT, THan, and THir have received research grants from FUJIFILM Corporation. THan is employed by Collaborative Research Laboratory funded by Teijin Pharma Co., Ltd. KIyo, KK, NH, KF, JM, MY, KM, and MS have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study protocol and informed consent documents have been approved by the Institutional Review Boards of Kumamoto University Hospital (approval number: 2368), Saiseikai Kumamoto Hospital (approval number: 809), and each participating institution. Additionally, written informed consent will be obtained from all participants. Patient recruitment commenced on 20 June 2022. When we use human tissue or blood samples, all methods were carried out in accordance with relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent including the use of personal examination data or images will be obtained from all participants. If we cite personal data such as text\/figures\/tables\/images, we strictly do anonymization not to identify the participants themselves.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"199"}}